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Abstract: Angiotensin II (AngII) is the biologically active peptide of the renin-angiotensin system (RAS). Tis-
sue-based, local RAS has been identified in the prostate, testis, epididymis and coagulating glands. Experimen-
tal and clinical studies have consistently shown that myocardial infarction (MI) is associated with activation of
the systemic RAS with increased concentration of angiotensin peptides in the blood and changes in expression
of angiotensin receptors (AT). Changes in angiotensin receptors in the renal and cardiovascular system after MI
are well recognized, but the effects of MI influence on changes in other tissue like the prostate gland are un-
known. In the present study, we investigated the effect of myocardial infarction on angiotensin receptor protein
and mRNA expression in the rat prostate gland. MI model was established in Wistar rats by ligating the left
coronary artery (modified Selye method). The levels of AT1a-b and AT2 receptor mRNAs and proteins were
measured in the rat prostate. Our study demonstrates tissue-specific changes in AT1a-b and AT2 receptor ex-
pression after myocardial infarction. The results show that MI has a strong influence on the expression of angio-
tensin receptor type AT1 in the prostate at the protein and mRNA level. (Folia Histochemica et Cytobiologica
2011, Vol. 49, No. 3, 497–503)
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Introduction
Angiotensin II (AngII), the biologically active pep-
tide of the renin-angiotensin system (RAS), is a ma-
jor regulator of blood pressure and cardiovascular
homeostasis, and is also recognized as a potent mito-
gen [1, 2]. Tissue-based, local RAS components have
been identified in the prostate, testis, epididymis, co-
agulating glands, ovary, uterus, placenta, brain, heart,
peripheral blood vessels, adrenal glands, and kidney
[3, 4]. The ability of RAS sites in the testis, epididy-
mis and prostate to synthesize AngII have been re-
ported in recent years [4–6]. AngII concentrations in
the seminal plasma are three to five times higher than
in blood plasma. This information may indicate an
important role for the RAS in the prostate. Heart fail-
ure and myocardial infarction are progressive disor-
ders in which damage to the heart causes weakening
of the cardiovascular system. It is manifested by fluid
congestion or inadequate blood flow to tissues.
A myocardial infarction initiates in the heart a sequence
of humoral, neurogenic and hemodynamic events
which influence the function of the heart and of re-
mote organs. This progressive disorder must be man-
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aged with regard to not only the state of the heart,
but the condition of the circulation, lungs, neuroen-
docrine system and perhaps other organs like the pros-
tate as well [7, 8]. Several experimental and clinical
studies have consistently shown that a myocardial in-
farction is associated with activation of the systemic
RAS, and consequently increased concentration of
angiotensin peptides in the blood and changes in an-
giotensin receptors (AT) expression [7, 9]. The phys-
iological actions of the bioactive angiotensin peptides
depend on their chemical structure and on their spec-
ificity for the membrane receptors, the information
transducers at the cellular level [10, 11]. AngII is the
first, and the most active, multifunctional hormone
of the RAS [12]. Its interactions with the specific an-
giotensin receptors trigger complex cellular signaling
events, which have been extensively studied in vari-
ous organs and anatomical structures [13].
It is well known that AngII is a pivotal factor in
the RAS, and increases blood pressure in the system-
ic and local blood circulation. In particular, this pep-
tide affects the kidney and stimulates aldosterone
release from the adrenal gland [14, 15]. It is also now
known that AngII plays a key role in cardiac hyper-
trophy, heart failure, atherosclerosis and remodeling
[16, 17]. This confirms the hypothesis that the RAS is
expressed locally and that AngII directly functions as
a pathophysiological factor in cardiovascular and re-
nal diseases [18]. In mammalian cells, AngII binds to
two distinct high-affinity plasma membrane receptors,
AT1 and AT2. Two subtypes of the AT1 receptor (AT1a
and AT1b) have been identified in rodents, but not in
humans [12, 13]. AT1 receptor activation leads to vas-
cular contraction, inflammatory responses, salt and
water retention, and cell proliferation, whereas the
AT2 receptor induces apoptosis, vasodilation and
natriuresis. In the vasculature, AT1 receptors are ex-
pressed in the smooth muscle cells, while in the hu-
man prostate, autoradiography and immunohis-
tochemistry show that AT1 receptors are localized to
stromal smooth muscle, confirmed by staining for
smooth muscle actin [19]. At these levels, AngII pro-
motes its effects via angiotensin receptors, which trig-
ger intracellular signaling processes, including cross-
talk with pathways activated by other vasoactive
agents, and are accompanied by the release of other
bioactive factors. In response to AngII stimulation,
AT1 receptors interact with various heterotrimeric
G proteins inducing the phosphorylation of tyrosine-
-kinases [20]. Binding of AngII to AT1 receptor results
in internalization of the AT1-AngII complex. While the
receptor is recycled back to the plasma membrane,
AngII is destined for intracellular locations such as ly-
sosomes and the nucleus [13, 21]. The intracellular
signaling processes are multiphasic, leading to vari-
ous biological actions. The AT1-receptor activation
leads to increased protein tyrosine phosphorylation
and to the activation of mitogen-activated protein-
-kinase (MAPK). These processes are associated with
growth factors and cytokines as pleiotropic and in-
flammatory agents. Thus, in addition to its potent vas-
oconstrictor actions, AngII has proliferative and pro-
inflammatory properties [11, 22]. There are a few
possible functions for the AT1 receptor in the differ-
ent prostatic cell types. The presence of AT1 recep-
tors is highly characteristic of many secretory epithe-
lia, including in the fallopian tube, renal proximal
tubule or pancreas [5, 23, 24]. The presence of the
AT1 receptor in vascular smooth muscle cells may
suggest that AngII is able to contribute to regulating
prostatic blood flow and the presence of these recep-
tors in the stromal smooth muscle cells may have
a role in modulating muscle tone, cell growth and con-
trol of migration [25].
Uemura et al. demonstrated that activation of
AT1receptors in LNCaP, DU145 and PrSC cells stim-
ulates mitogen activated protein kinase (MAPK),
Janus tyrosine kinase-signal transducers, activators of
transcription (STAT), and cell proliferation [26–28].
Many studies confirm that AngII acting via the AT1
receptor may have a role in the development and pro-
gression of prostate cancer [27, 29–31]. Other exper-
iments support the hypothesis that prostatic stromal
cells are involved in the promotion of growth factor
activity, and may contribute to the initiation and de-
velopment of prostate cancer [3, 27, 30, 32]. Whereas
changes in angiotensin receptor expression in the re-
nal and cardiovascular systems after myocardial inf-
arction are well recognized, the effects of myocardial
infarction on changes in other tissue like the prostate
gland are not known. In the present study, we investi-
gated the effect of myocardial infarction on angio-
tensin receptor expression at the level of protein and
mRNA expression in the rat prostate gland.
Material and methods
Ethical considerations. All experimental procedures in-
volving the animals were approved by the Local Committee
for Ethics in Animal Experimentation of the Medical Uni-
versity of Lodz, Poland. The experiments were performed
in accordance with the Committee’s guidelines.
Animals. Adult Wistar rats weighing 260 g ± 30 g (mean ±
± SEM) were housed with free access to commercial food
pellets (LSM), as well as tap water ad libitum. All the rats
were kept in 12 h:12 h Light-Dark (LD) conditions. Rats
were divided into two groups: 1) controls (C) composed of
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sham operated rats, 2) animals with myocardial infarction
(MI) induced by ligation of the left coronary artery. Each
group contained ten rats, not older than five months. Twen-
ty eight days after ligation of the coronary artery, the rats
were killed under ether anesthesia and the prostate glands
were removed and dissected. One lobe of the ventral pros-
tate was formalin-fixed and paraffin-embedded for histo-
logical and immunohistochemical studies. Another lobe was
frozen in liquid nitrogen and kept at –80°C until RNA iso-
lation and Western-blot analysis.
Myocardial infarction model. Left coronary artery liga-
tion was performed according to the Selye method with our
modification [33]. To prevent ventricular arrhythmias, all
rats were treated with 2 mg/kg of lignocaine intraperito-
neally (i.p.). The rats were anesthetized with pentobarbital
at the dose of 50 mg/kg i.p. and ventilated with positive pres-
sure through a tube inserted into the trachea and connect-
ed to a small animal respirator (Kent Scientific Corpora-
tion, RSP1002). A 2 cm long craniocaudal incision of the
skin and pectoral muscles was made and then the intercos-
tal muscles were cut between the fifth and sixth ribs. After
opening the pericardium, the heart was gently exteriorized
and the left coronary artery was ligated with 6/0 nylon su-
tures. The ligation was made between the left margin of the
pulmonary cone and the closest point of insertion of the
left auricular appendage. The heart was returned to the tho-
rax and after closing the muscles and the skin, the lungs
were expanded. The sham operation comprised the same
surgical procedure, but the left coronary artery was not li-
gated. After surgery, all animals were injected with penicil-
lin (200,000 units/animal). After four weeks, all rats were
killed humanely, and their prostate glands and hearts were
obtained.
Immunohistochemistry. The prostate glands were histo-
logically analyzed by standard methods. 5-μm-thick sections
were cut and placed on glass slides and stained with hema-
toxylin and eosin for identification of histologically distinct
tissue regions. AT1 immunostaining was performed using
the anti-AT1 polyclonal antibody sc-1173 (Santa Cruz Bio-
technology). This antibody was raised against the N-termi-
nal extracellular domain of the AT1 receptor and recogniz-
es human, rat and mouse receptor protein. AT2 receptors
were revealed using the sc-9040 (Santa Cruz Biotechnolo-
gy) polyclonal antibody raised against the 221-303 fragment
of the AT2 receptor protein. The antibody detects human,
rat and mouse AT2 receptors. The anti-AT1 and anti-AT2
antibodies were applied in a working dilution of 1:100. The
visualization of primary anti-receptor antibodies was done
using the StreptABComplex/HRP Duet (Dako) following
the procedure recommended by the manufacturer. In brief,
a biotinylated goat antibody against rabbit and mouse im-
munoglobulin was applied as the secondary antibody, fol-
lowed by streptavidin-biotinylated horseradish peroxidase
complex and 3,3’-diaminobenzidine as chromogen. The
slides were analyzed in a light microscope (Olympus Opti-
cal Co. Ltd.). The evaluation procedure was performed us-
ing MICRO IMAGETM software (Olympus Optical Co.
Ltd.). The optical density (OD), calculated by multiplica-
tion of the area of cell labeling and density, was used for
evaluation of receptor expression. At least 20 randomly cho-
sen visual fields per slide were examined.
Immunoblotting. Total protein from frozen prostate tissues
was extracted in RIPA protein extraction buffer consisting
of 50 mM Tris HCl (pH 8.0), 150 mM NaCl, 0.5% Na Doc,
0.1% NP-40, 0.1% SDS, 2 mM EDTA, supplemented with
protease and phosphatase Inhibitor Cocktail (Sigma–Ald-
rich P8340, P6726) and 1 mM PMSF. The lysate was centri-
fuged at 14,000 × g and 4°C for 20 min, and the pellet dis-
carded. Protein concentrations were determined by the
method of Bradford (Bio-Rad Laboratories, Hercules, CA,
USA) according to the manufacturer’s protocol and using
bovine serum albumin as a standard. Tissue homogenates
were mixed in a 3:1 ratio with 4-fold concentrated Laemmli
buffer (Bromophenol blue, 40% glycerol, 8–10% SDS, 20%
b-mercaptoethanol), heated for 2–5 min at 100°C and de-
posited on the gel at 50 mg of protein per track. Protein
samples were subjected to 10% SDS-PAGE and electro-
phoretically transferred to a PVDF membrane (Sigma-Al-
drich P2938). The membrane was preincubated in 5% non-
-fat milk in TBST (20 mM Tris-HCL, 500 mM NaCl, 0.05%
Tween-20, pH 7.5) for 1 hour at room temperature. After
this time, the membranes were incubated for 12 h at 4°C
with the addition of selected primary antibodies (Santa Cruz
Biotechnology Inc.). At the end of the overnight incuba-
tion, the membrane was washed three times (3 × 15 min)
with TBST and incubated for one hour in a solution of 5%
milk powder in TBST containing the appropriate second-
ary antibodies conjugated with horseradish peroxidase (San-
ta Cruz Biotechnology Inc.). After incubation with second-
ary antibodies, the membrane was washed three times
(3 × 15 min) in TBST buffer. The chemiluminescent reac-
tion was induced using ECL (GE Healthcare UK Ltd).
Bands were visualized by capture on X-ray film. Densito-
metric analysis of protein levels was performed with Im-
ageJ 1.34s software (Wayne Rasband, National Institutes
of Health, USA; http://rsb.info.nih.gov) and the results were
expressed as optical density (OD). The results were nor-
malized for GAPDH OD.
Reverse transcription Polymerase Chain Reaction. To-
tal RNA was extracted from rat prostate homogenates
using the RNeasy mini kit (Qiagen Ltd., West Sussex,
UK). RT-PCR primers were designed from mRNA se-
quences published in NCBI, with the Primer3 program
(http://frodo.wi.mit.edu/primer3/), Table 1. Primers were syn-
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thesized in the Oligo IBB PAN (Institute of Biochemistry
and Biophysics, Poland). RT-PCR was carried out from
1 μg total RNA with reagents from the Access RT-PCR Sys-
tem kit (Promega, UK), following the manufacturer’s in-
structions. PCR products were separated on 1.5% agarose
gels and visualized under UV light. Densitometric analysis
of each band was performed with ImageJ 1.34s software
(Wayne Rasband, National Institutes of Health, USA) and
the results were expressed as optical density (OD). GAP-
DH was used as an internal standard. The densitometry
values were normalized against the GAPDH values and
expressed as band OD compared to the control group.
Statistical analysis was performed with GraphPad Prism 4
software (GraphPad Software, Inc). All results are expressed
as mean values ± SEM. t-test, one-way ANOVA and New-
man–Keuls test were employed to determine significant dif-
ferences, with an accepted level of significance of p < 0.05.
Results
Determination of infarct sizes
To evaluate whether myocardial infarctions were of
similar extent among rats, the infarct sizes were mi-
cromorphometrically evaluated. The hearts were di-
vided into the left ventricle, right ventricle, scar and
septum, then the weight of all parts was measured.
The mean scar weight was 34.7 ± 14.5 mg/100 g b.w.
The ratio of the surface area of the scar to the wall of
the left ventricle was mean 37.7% ± 6.9%.
Angiotensin receptor level in the prostate
Immunohistochemistry
Twenty eight days after surgery, a statistically signifi-
cant increase in the number of AT1 receptors was
observed by immunohistochemical staining of rat
prostate sections. The mean OD value for AT1 re-
ceptor in the epithelium in the control group of rats
was 58.66 ± 6.09 and for the infarct group 198.4 ±
± 31.69 (p < 0.01). For the stroma, these values were
242.2 ± 28.61 (control group), and for the infarct
group 465.5 ± 66 (p < 0.05). In the epithelium, the
density of AT1 receptors was increased by 3.38-fold
compared to the control group. In the stroma, it was
increased by 1.9 fold (p < 0.05) compared to the con-
trol group (Figure 1 panels A and B).
In the case of AT2 receptors, we observed a de-
crease in the density of the receptors of 0.95-fold in
the epithelium and 0.78-fold in the stroma. Mean OD
value for the AT2 receptor in the control group was
63.85 ± 17 in the epithelium and 264.3 ± 32.05 in the
stroma. In the infarct group, the mean OD value for
the epithelium was 61.13 ± 10.45 and 206.7 ± 21.67
for the stroma. The respective values were not signif-
icantly different (Figure 1 panels C and D).
Immunoblotting assay
Immunoblotting assay showed that the total quantity
of AT1 receptor protein was greater in rats with myo-
Figure 1. Immunocytochemistry of rat prostate sections
using the anti AT1 and AT2 monoclonal antibody. Localiza-
tion of antigens is indicated by brown staining (A, C).
The scale bars are 100 μm. The histograms represent the
mean value optical densities (OD) of AT1 (B) and AT2 (D).
The OD intensity is given on an arbitrary scale in arbitrary
units [a.u.]. Asterisk indicates significant differences
(*p < 0.05; **p < 0.01) (mean ± SEM) compared to controls
Table 1. Primer sequences used for AT1a, AT1b, AT2 receptor and GAPDH
Gene name Gen Bank Primer Product size
accession number  sequences  (bp)
Angiotensin II receptor, type 1a [Rattus norvegicus] 24180 5’-GGAAACAGCTTGGTGGTGAT-3’ 171
5’-ACATAGGTGATTGCCGAAGG-3’
Angiotensin II receptor, type 1b [Rattus norvegicus] 81638 5’-GGAAACAGCTTGGTGGTGAT-3’ 189
5’-GCTGGCAGAAGCGATCTTAC-3’
Angiotensin II receptor, type 2 [Rattus norvegicus] 24182 5’-AACCGGCAGATAAGCATTTG-3’ 160
5’-AAGTCAGCCACAGCCAGATT-3’
Glyceraldehyde-3-phosphate dehydrogenase 24383 5’-ATGGGAAGCTGGTCATCAAC-3’ 221
[Rattus norvegicus] 5’-GTGGTTCACACCCATCACAA-3’
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cardial infarction. Mean optical density value for AT1
normalized for GAPDH optical density in the con-
trol group was 0.42 ± 0.07 and in the infarct group
0.97 ± 0.14 (p < 0.05). This increase was 2.3-fold and
statistically significant (Figures 2 A and B). In the case
of the AT2 receptor protein, a decrease in AT2 re-
ceptor protein 0.93 ± 0.13 times was observed. Mean
OD value for AT2 normalized for GAPDH in the
control group was 0.80 ± 0.08 and in the infarct group
0.74 ± 0.06. These values were not statistically signif-
icant (Figures 2C and D).
Reverse transcription Polymerase Chain Reaction for
AT1 receptor and AT2 receptor mRNA in the rat prostate
The effects of myocardial infarction on mRNA ex-
pression for AT1a and AT1b receptors in the prostate
are shown in Figure 3. Gel electrophoresis of PCR
products show there was an increase in the mRNA
level of both the AT1a and AT1b receptors (9.3 and
7.9-fold, respectively) in the MI group compared to
the control group. The observed increase was statis-
tically significant for both AT1 receptors (p < 0.05;
p < 0.01). The level of AT2 receptor mRNA was
0.89-fold lower after myocardial infarction, but there
was no statistically significant difference in the level
of AT2 mRNA between the groups.
Discussion
The present study demonstrates tissue-specific chang-
es in expression of AT1 and AT2 receptor after myo-
cardial infarction (MI). The results show that MI has
an evident influence on the expression of angiotensin
receptor type 1 (AT1) in prostate tissue. These changes
comprise both protein and mRNA level.
Numerous studies have shown that MI has a sig-
nificant impact on changes in the RAS system com-
ponents, such as expression of angiotensin receptors,
or angiotensin-converting enzyme activity in various
tissues [7, 34–36]. In vivo and in vitro experiments
have shown that MI provokes a dramatic up-regula-
tion of both angiotensin receptor subtypes in differ-
ent organs [34, 37, 38]. Busche et al. have shown that
cardiomyocytes express AT1 and AT2 receptor mRNA
under physiological conditions, but the number of
cells expressing these receptors is not increased after
myocardial infarction [34]. In another study per-
formed on rats, Tan et al. observed that after MI there
is a significant increase in AT1 receptor and ACE
densities, not only in the heart, but also in brain nu-
clei [39]. Also experiments by Milik et al. demonstrat-
ed a significant increase of AT1a mRNA in the heart
and kidney after MI, thereby suggesting that the my-
ocardial infarct initiates in these organs the process-
es which may finally result in increased synthesis of
AT1a receptor protein [7].
Although AngII is well known to be an important
factor in hypertension, it has also been reported to
play a central role in proliferation and/or differentia-
tion via AT1 receptor in specific organs, linking it to
the progression of cancer [40]. Changes in RAS com-
ponents have been identified in various cancer types
in humans and animals, and it has been reported that
the AT1 receptor is involved in the proliferation of
various cancers in vitro and in vivo [26, 41–43]. Stud-
ies by Suganuma [44] showed that AT1 receptor ex-
Figure 2. Effects of myocardial infarction on the expres-
sion of AT1 and AT2 receptor protein in rat prostate.
Upper panels (A, C) present representative Western-blot
of AT1 (A) and AT2 (C) receptor protein. Histograms B
and D represent the mean value ratio of optical densities
(OD) of AT receptor protein/GAPDH. Asterisk indicates
significant differences (*p < 0.05) (mean ± SEM) compa-
red to controls
Figure 3. RT-PCR demonstrated expression level of
angiotensin receptor mRNA in rat prostate. Upper panels
(A, C) present representative bands of AT1a, AT1b mRNA
(A) and AT2 mRNA (C). Left part of panels A and C
presents Control group, right part Infarct group. The histo-
grams B and D represent the mean value of AT mRNA OD.
Asterisk indicates significant differences (*p < 0.05;
**p < 0.01) (mean ± SEM) compared to controls
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pression was dramatically up-regulated during the
progression from benign to malignant phenotypes of
ovarian tumors. AT1 was expressed in 85% of inva-
sive ovarian carcinomas and was not dependent on
the histopathologic subtype. Marsigliante et al.
showed that the human larynx expresses the AT1 re-
ceptor type, and that it is dramatically increased in
well differentiated cancer cells [45]. Studies of cervi-
cal carcinoma cells demonstrated that the AT1 recep-
tor is present in these cells and that AngII enhances
invasive potency by increasing the secretion of vascu-
lar endothelial growth factor (VEGF) through the
AT1 receptor. Angiotensin activity mediated via AT1
receptor is also involved in the progression of cervi-
cal carcinoma, as it induces the secretion of VEGF,
which results in the increased invasiveness of carci-
noma cells [46]. Uemura et al. presented strong evi-
dence of the influence of AngII and AT1 receptor
blockers on prostate cancer cells and tumor growth
of prostate cancer [18]. They noted that AngII en-
hances proliferation of prostate cancer cells via sig-
naling pathway that includes activation of AT1 recep-
tor MAPK and STAT3. Moreover, the cell prolifera-
tion induced by AngII was similar in androgen-de-
pendent and androgen-independent cancer cells
(LNCaP and DU145). Expression of AT1 receptor
protein in the normal human prostate and benign
prostatic hyperplasia is localized on stromal smooth
muscle, while AngII peptide is localized in the basal
layer of the epithelium, suggesting that AngII is medi-
ating cellular growth and smooth muscle tone in the
human prostate in a paracrine manner [25].
These preliminary results indicate that MI is a fac-
tor which could provoke the changes in AT1 receptor
expression in prostate tissue. Based on the observa-
tions of other authors, we can suppose that an increase
in the number of AT1 receptors may cause excessive
cell proliferation [40, 47].
It seems that increasing the number of receptors
in the stroma could be a key factor for the future
cause of neoplastic lesions of the prostate. Cell pro-
liferation can be activated by angiotensin II in two
ways: directly and indirectly. The direct way involves
the mechanism of activating the AngII via AT1 re-
ceptor. The indirect activation starts with the AT1
receptor (activated by angiotensin), which mediates
the intracellular signal regulating the androgen re-
ceptors, which are responsible for cell proliferation
or hypertrophy.
It is very probable that changes in the balance be-
tween AT1 and AT2 receptors in the prostate gland,
which occur as a result of a myocardial infarction, may
be the cause of hypertrophy of the prostate. We can-
not exclude that the far-reaching consequence of the
imbalance of homeostasis can be the process of car-
cinogenesis in this tissue. In conclusion, it seems es-
sential to pay greater attention to the consequences
of cardiovascular failure in the context of distant tis-
sues such as the prostate.
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